Epstein-Barr virus (EBV) exacerbates inflammatory bowel disease (IBD) and is challenging to monitor with invasive or costly tests. We investigated whether explainable machine learning can predict EBV infection from routine clinical data in ulcerative...
Inflammatory bowel disease (IBD), including Crohn's disease and Ulcerative colitis, often shows variable responses to biological therapies. Identifying the most significant variables for predicting the response to these therapies could help prioritiz...
Our study explores signatures for Crohn's disease (CD) and Ulcerative Colitis (UC) reflecting an interplay between the intestinal microbiota, systemic inflammation, and plasma bile acid homeostasis. For this, 1,257 individuals scheduled for colonosco...
Crohn's disease (CD), a chronic inflammatory bowel disease, is witnessing a rising global incidence. Adalimumab (ADA), a biological agent, is widely used in its treatment. However, patients exhibit significant individual variability in responses to A...
Crohn's disease (CD) is a chronic inflammatory bowel condition that significantly impairs patients' quality of life. With no cure currently available, the need to discover novel biomarkers and develop effective therapeutic strategies is paramount. Th...
The relationship between interleukin-22 and clinical characteristics of patients with inflammatory bowel disease is uncertain. We sought to determine whether plasma interleukin-22 concentrations are associated with disease activity in a large populat...
BACKGROUND: Accurate identification of anal fistulas is essential, as it directly impacts the severity of subsequent perianal infections, prognostic indicators, and overall treatment outcomes. Traditional manual recognition methods are inefficient. I...
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory bowel disease, with infliximab (IFX) commonly used for treatment. However, no clinically applicable model currently exists to predict the response of patients with CD to IFX therapy. Given th...
The lancet. Gastroenterology & hepatology
Jul 1, 2025
BACKGROUND: Biological therapeutics are widely used in Crohn's disease, with evidence of efficacy from randomised trials and real-world experience. Primary non-response is a common, poorly understood problem. We aimed to assess blood methylation as a...
Gut microbiota has been implicated in the pathogenesis of multiple gastrointestinal (GI) and systemic metabolic and inflammatory disorders where disrupted gut microbiota composition and function (dysbiosis) has been found in multiple studies. Thus, h...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.